160 related articles for article (PubMed ID: 20232090)
1. Phage display peptide probes for imaging early response to bevacizumab treatment.
Cao Q; Liu S; Niu G; Chen K; Yan Y; Liu Z; Chen X
Amino Acids; 2011 Nov; 41(5):1103-12. PubMed ID: 20232090
[TBL] [Abstract][Full Text] [Related]
2. A Cy5.5-labeled phage-displayed peptide probe for near-infrared fluorescence imaging of tumor vasculature in living mice.
Chen K; Yap LP; Park R; Hui X; Wu K; Fan D; Chen X; Conti PS
Amino Acids; 2012 Apr; 42(4):1329-37. PubMed ID: 21212998
[TBL] [Abstract][Full Text] [Related]
3. Monitoring hypoxia and vasculature during bevacizumab treatment in a murine colorectal cancer model.
Heijmen L; Ter Voert EG; Punt CJ; Heerschap A; Oyen WJ; Bussink J; Sweep CG; Laverman P; Span PN; de Geus-Oei LF; Boerman OC; van Laarhoven HW
Contrast Media Mol Imaging; 2014; 9(3):237-45. PubMed ID: 24700751
[TBL] [Abstract][Full Text] [Related]
4. Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging.
O'Connor JP; Carano RA; Clamp AR; Ross J; Ho CC; Jackson A; Parker GJ; Rose CJ; Peale FV; Friesenhahn M; Mitchell CL; Watson Y; Roberts C; Hope L; Cheung S; Reslan HB; Go MA; Pacheco GJ; Wu X; Cao TC; Ross S; Buonaccorsi GA; Davies K; Hasan J; Thornton P; del Puerto O; Ferrara N; van Bruggen N; Jayson GC
Clin Cancer Res; 2009 Nov; 15(21):6674-82. PubMed ID: 19861458
[TBL] [Abstract][Full Text] [Related]
5. Measurement of tumor VEGF-A levels with 89Zr-bevacizumab PET as an early biomarker for the antiangiogenic effect of everolimus treatment in an ovarian cancer xenograft model.
van der Bilt AR; Terwisscha van Scheltinga AG; Timmer-Bosscha H; Schröder CP; Pot L; Kosterink JG; van der Zee AG; Lub-de Hooge MN; de Jong S; de Vries EG; Reyners AK
Clin Cancer Res; 2012 Nov; 18(22):6306-14. PubMed ID: 23014526
[TBL] [Abstract][Full Text] [Related]
6. Does imaging αvβ3 integrin expression with PET detect changes in angiogenesis during bevacizumab therapy?
Rylova SN; Barnucz E; Fani M; Braun F; Werner M; Lassmann S; Maecke HR; Weber WA
J Nucl Med; 2014 Nov; 55(11):1878-84. PubMed ID: 25278514
[TBL] [Abstract][Full Text] [Related]
7. Monitoring therapeutic monoclonal antibodies in brain tumor.
Ait-Belkacem R; Berenguer C; Villard C; Ouafik L; Figarella-Branger D; Beck A; Chinot O; Lafitte D
MAbs; 2014; 6(6):1385-93. PubMed ID: 25484065
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.
Pohl M; Werner N; Munding J; Tannapfel A; Graeven U; Nickenig G; Schmiegel W; Reinacher-Schick A
Z Gastroenterol; 2011 Oct; 49(10):1398-406. PubMed ID: 21964893
[TBL] [Abstract][Full Text] [Related]
9. Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer.
Bruhn MA; Townsend AR; Khoon Lee C; Shivasami A; Price TJ; Wrin J; Arentz G; Tebbutt NC; Hocking C; Cunningham D; Hardingham JE;
Int J Cancer; 2014 Aug; 135(3):731-41. PubMed ID: 24374727
[TBL] [Abstract][Full Text] [Related]
10. A novel vascular-targeting peptide for gastric cancer delivers low-dose TNFα to normalize the blood vessels and improve the anti-cancer efficiency of 5-fluorouracil.
Lu L; Li ZJ; Li LF; Shen J; Zhang L; Li MX; Xiao ZG; Wang JH; Cho CH
Peptides; 2017 Nov; 97():54-63. PubMed ID: 28970092
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
Hsu JY; Wakelee HA
BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
[TBL] [Abstract][Full Text] [Related]
12. Monitoring the effects of bevacizumab beyond progression in a murine colorectal cancer model: a functional imaging approach.
Heijmen L; Punt CJ; Ter Voert EG; de Geus-Oei LF; Heerschap A; Bussink J; Sweep CG; Zerbi V; Oyen WJ; Span PN; Boerman O; van Laarhoven HW
Invest New Drugs; 2013 Aug; 31(4):881-90. PubMed ID: 23325291
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab reduces tumor targeting of antiepidermal growth factor and anti-insulin-like growth factor 1 receptor antibodies.
Heskamp S; Boerman OC; Molkenboer-Kuenen JD; Oyen WJ; van der Graaf WT; van Laarhoven HW
Int J Cancer; 2013 Jul; 133(2):307-14. PubMed ID: 23335047
[TBL] [Abstract][Full Text] [Related]
14. Application of peptide displaying phage as a novel diagnostic probe for human lung adenocarcinoma.
Lee KJ; Lee JH; Chung HK; Ju EJ; Song SY; Jeong SY; Choi EK
Amino Acids; 2016 Apr; 48(4):1079-1086. PubMed ID: 26759016
[TBL] [Abstract][Full Text] [Related]
15. Anti-angiogenic therapies for metastatic colorectal cancer.
Wagner AD; Arnold D; Grothey AA; Haerting J; Unverzagt S
Cochrane Database Syst Rev; 2009 Jul; (3):CD005392. PubMed ID: 19588372
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer.
Krämer I; Lipp HP
J Clin Pharm Ther; 2007 Feb; 32(1):1-14. PubMed ID: 17286784
[TBL] [Abstract][Full Text] [Related]
17. Early antivascular effects of bevacizumab anti-VEGF monoclonal antibody on colorectal carcinomas assessed with functional CT imaging.
Koukourakis MI; Mavanis I; Kouklakis G; Pitiakoudis M; Minopoulos G; Manolas C; Simopoulos C
Am J Clin Oncol; 2007 Jun; 30(3):315-8. PubMed ID: 17551312
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant treatment of colorectal cancer with bevacizumab: the perioperative angiogenic balance is sensitive to systemic thrombospondin-1 levels.
Brostjan C; Gebhardt K; Gruenberger B; Steinrueck V; Zommer H; Freudenthaler H; Roka S; Gruenberger T
Clin Cancer Res; 2008 Apr; 14(7):2065-74. PubMed ID: 18381946
[TBL] [Abstract][Full Text] [Related]
19. Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts.
Miyazaki S; Kikuchi H; Iino I; Uehara T; Setoguchi T; Fujita T; Hiramatsu Y; Ohta M; Kamiya K; Kitagawa K; Kitagawa M; Baba S; Konno H
Int J Cancer; 2014 Jul; 135(2):295-307. PubMed ID: 24375080
[TBL] [Abstract][Full Text] [Related]
20. Temsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models.
Fleuren ED; Versleijen-Jonkers YM; Roeffen MH; Franssen GM; Flucke UE; Houghton PJ; Oyen WJ; Boerman OC; van der Graaf WT
Int J Cancer; 2014 Dec; 135(12):2770-82. PubMed ID: 24771207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
